Hydroxyurea capsules

This product is a nucleoside diphosphate reductase inhibitor that can prevent nucleotides from being reduced to deoxynucleotides, thereby selectively inhibiting DNA synthesis, inhibiting the incorporation of thymine nucleotides into DNA, and directly damaging DNA, but has no inhibitory effect on the synthesis of RNA and proteins. This product is a cell cycle-specific drug that acts on the S phase and can block some cells to the edge of the G1/S phase, so it can be used as a drug to synchronize some cancer cells or to enhance radiosensitivity.

The main ingredient of this product and its chemical name is: hydroxyurea.

This product is a capsule containing white crystalline powder, which is odorless and tasteless and easily soluble in water.

It has a positive effect on both intractable psoriasis and pustular psoriasis, and can reduce the pus scars, fever and poisoning symptoms of systemic pustular psoriasis. For short-term use, its toxicity is less than that of methotrexate. It seems that this product is suitable for patients with severe psoriasis who have liver damage and are not suitable for methotrexate or who are ineffective with methotrexate.

1. Common dosage for adults (1) For CML, the dosage can be determined based on the patient's condition and white blood cell count before medication. The general starting dosage is 20-30 mg/kg per day, taken orally once or twice. When the white blood cell count drops below 10×109/L, the dosage is reduced to about 20 mg/kg per day, taken orally or intermittently. (2) For head and neck cancer, ovarian cancer, etc., the dosage is 60-80 mg/kg per day, or 2000-3000 mg/m2 per body surface area, twice a week, taken alone or in combination with radiotherapy; it can also be taken orally once a day at 20-30 mg/kg per day. 2. Common dosage for children: not yet determined.

1. Hematopoietic system: The most common symptoms are leukopenia, thrombocytopenia, anemia or abnormal red blood cell morphology. 2. Digestive system: The most common symptoms are decreased appetite, nausea, vomiting, and less common are constipation. Long-term use of this product may cause oral mucositis, oral ulcers, diarrhea, etc. 3. Others: Skin reactions such as rash, erythema, itching, darkening of skin color, and hair loss are relatively rare. Increased blood uric acid or uric acid nephropathy may occur occasionally. Neurotoxic manifestations such as headache, drowsiness, dizziness, hallucinations, convulsions, and drug-induced fever are occasionally seen.

1. It is contraindicated for patients with chickenpox or herpes zoster. 2. It is contraindicated for patients with various serious infections.

Precautions for children: Not clear. Precautions for pregnancy and lactation: Pregnant women should avoid taking this drug within the first 3 months of pregnancy or during lactation. Precautions for the elderly: Elderly patients should reduce the dose appropriately.

1. When this product is used in combination with allopurinol, colchicine, probenecid, etc. to treat gout, the dosage of the above anti-gout drugs must be adjusted to control gout lesions and blood uric acid concentrations. This product can prevent and reverse hyperuricemia caused by this product when used in combination with allopurinol. 2. When used in combination with drugs that can cause leukocytopenia or thrombocytopenia or with radiotherapy, the patient's blood picture should be closely observed and the dosage of this product should be appropriately adjusted accordingly. 3. This product has no cross-resistance with alkylating agents and radiation. 4. This product has an inhibitory effect on the central nervous system and can cause drowsiness. When used in combination with pentobarbital, methaqualone nitrazepam, anesthetics, phenothiazines, tricyclic antidepressants, etc., pay attention to adjusting the dosage after additive effects occur.

seal.

0.25g

36 months

Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd.

• Founded in:

  1992-06-12

• Address:

  No. 908, Jicheng Road, Huitong Industrial Park, Jinzhong Development Zone, Shanxi Demonstration Zone, Jinzhong City, Shanxi Province

• Tax NO.:

  91140700602052641X

• Registered Funds:

  170 million yuan

• Website:

  Log in to view

• Email:

  Log in to view